Dr. Weber on Emerging Therapies in Melanoma

In Partnership With:

Partner | Cancer Centers | <b>NYU Langone's Perlmutter Cancer Center</b>

Jeffrey S. Weber, MD, PhD, discusses emerging therapies in melanoma.

Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone Health’s Perlmutter Cancer Center; Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine; and the 2016 Giant of Cancer Care® in Melanoma, discusses emerging therapies in melanoma.

In the future, the field can expect to see novel agents used in combination with tumor​-infiltrating lymphocyte therapy, as well as novel checkpoints such as sialic acid-binding immunoglobulin-type lectins, says Weber.

Moreover, research evaluating bispecific molecules targeting PD-1, CTLA-4, inducible T-cell co​stimulator, and ​OX40 ​is ongoing, ​explains Weber.

Additionally, triplet regimens with immunotherapy may be evaluated as a means to overcome resistance, Weber concludes.